Literature DB >> 2966771

Autologous mixed lymphocyte-tumor reaction and autologous mixed lymphocyte reaction. II. Generation of specific and non-specific killer T cells capable of lysing autologous tumor.

A Uchida1, M Moore, E Klein.   

Abstract

The specific and non-specific nature of autotumor cytotoxicity induced in autologous mixed lymphocyte-tumor culture (AMLTC) and autologous mixed lymphocyte culture (AMLC) was studied in patients with carcinomatous pleural effusions. Small- and medium-sized blood lymphocytes that were isolated by centrifugation on discontinuous Percoll gradients did not lyse autologous, freshly isolated effusion tumor cells. In vitro activation of the small lymphocytes, but not of the medium lymphocytes, with autologous tumor cells generated cytotoxic potential restricted to autologous tumor. When stimulated with autologous non-malignant non-T cells, the medium lymphocytes, but not small lymphocytes, were triggered to cytotoxicity that acted not only on autologous tumor cells but also on allogeneic tumor cells, T blasts, and tumor cell lines. Experiments using monoclonal antibodies (MAb) and complement (C') showed that both types of killer cells were CD2+ CD3+ CD16- T cells. Autotumor cytotoxicity developed in AMLTC was mediated by the CD4- CD8+ T cell subset in 6 of 9 cases and the CD4+ CD8- subset in the other 3 cases. In contrast, cytotoxicity induced in AMLC was exerted exclusively by the CD8+ subset. The enrichment of blasts from cultured T cells on discontinuous density gradients enhanced autotumor killing activity, with no reactivity recorded for blast-depleted, resting T cells. Addition of mitomycin-C-treated large granular lymphocytes (LGL) to AMLTC abolished the induction of autotumor killer cells, whereas non-specific killer cells were generated in AMLC irrespective of the presence of LGL. These results indicate that stimulation of autoreactive T cells in AMLTC and in AMLC could induce 2 distinct types of autotumor killer cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966771     DOI: 10.1002/ijc.2910410502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines.

Authors:  A Uchida; T Fujimoto; Y Mizutani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Tumor-induced alteration in macrophage accessory cell activity on autoreactive T cells.

Authors:  A D Yurochko; P S Nagarkatti; M Nagarkatti; K D Elgert
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.

Authors:  J Atzpodien; H Kirchner
Journal:  Klin Wochenschr       Date:  1990-01-04

Review 4.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

5.  Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells.

Authors:  S Q Liu; R Shiba; B S Kim; K Saijo; T Ohno
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

6.  Human stomach carcinoma-specific T cells derived from the tumour-draining lymph nodes.

Authors:  K Stulle; H P Vollmers; P Marquardt; H K Müller-Hermelink
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

7.  Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK.

Authors:  Y Kariya; N Okamoto; T Fujimoto; N Inoue; T Kihara; K Sugie; M Yagita; H Kanzaki; T Mori; A Uchida
Journal:  Jpn J Cancer Res       Date:  1991-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.